News & Media
8/30/2016 | Press Release
Metamark Receives Positive Medicare Final Coverage Decision for ProMark
Metamark Genetics, Inc. today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses novel molecular diagnostic technologies, has issued final local coverage determination (LCD) for ProMark®, the first and only proteomic prognostic test for early-stage prostate cancer.
7/12/2016 | Press Release
Metamark Announces Agreement with Blue Cross and Blue Shield of Texas
Metamark Genetics, Inc., a leader in providing critical diagnostic and prognostic information to enable more informed treatment decisions for urological cancer, today announced that effective June 1, 2016, the Company signed an agreement with Blue Cross and Blue Shield of Texas (BCBSTX).
6/7/2016 | Press Release
Metamark Announces Agreement with Anthem Blue Cross Blue Shield of Georgia
Metamark Genetics, Inc., a leader in providing critical diagnostic and prognostic information to enable more informed treatment decisions for urological cancer, today announced that effective May 25, 2016, the Company has signed an agreement with Anthem Blue Cross Blue Shield of Georgia.
3/10/2016 | Press Release
ProMark® Prostate Cancer Prognostic now included in NCCN Guidelines
Metamark, a leader in commercializing high-value urologic oncology products, today announced that ProMark®, the first and only protein-based prognostic test for early-stage prostate cancer, has been included in the 2016 National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines.
10/19/2015 | Press Release
Study Demonstrates Cost-effectiveness of New Assay to Inform Treatment Decisions Compared to Guidelines-based Care
Data published in The Oncologist support use of ProMark® as a likely cost-effective addition to current guidelines for management of Gleason 3+3 and 3+4 early-stage prostate cancer.
3/9/2015 | Press Release
Metamark Announces Publication of Clinical Validation Study for the ProMark™ Prostate Cancer Prognostic Test
Metamark announced today that results of its clinical validation study for the ProMark™ prostate cancer test were published online in Clinical Cancer Research.
4/21/2015 | Press Release
Metamark Announces Partnership with Highmark Blue Shield to Provide Access to Comprehensive Urology Diagnostics
Metamark announced today that it has signed an agreement with Highmark Blue Shield to provide its members with in-network access to Metamark’s comprehensive suite of urology specialized diagnostic offerings.
10/9/2014 | Press Release
Metamark Laboratory Received Accreditation from College of American Pathologists
Cambridge Laboratory Will Serve as Primary Location for Processing ProMark™, the Company’s Newly-Launched Prostate Cancer Prognostic Test
10/9/2014 | Press Release
Metamark Announces Nationwide Availability of ProMark™ Prostate Cancer Test, First-of-its-Kind Protein-Based Prognostic Test
Metamark announced today the nationwide availability of ProMark™, the first-of-its-kind protein-based biopsy test designed to improve the accuracy of prognosis for men diagnosed with prostate cancer.
5/6/2014 | Press Release
METAMARK GENETICS INITIATES CLINICAL USE OF ProMark™
Metamark Genetics, Inc. today announced that it has initiated clinical use of the company’s ProMark™ prognostic test to help guide the medical management of patients with early-stage prostate cancer.
6/12/2014 | Press Release
Metamark Announces Appointment of Dr. Peter Blume-Jensen to its Scientific Advisory Board
Metamark today announced that its Chief Scientific Officer, Peter Blume-Jensen, M.D., Ph.D., will be joining a targeted therapeutics startup, and will continue working for Metamark as a member of the company’s Scientific Advisory Board and as a consultant.
6/2/2014 | Press Release
New Data Demonstrates ProMark™ Accurately Predicts Prostate Cancer Aggressiveness and Pathological Outcomes
ProMark™ has Potential to Transform Prostate Cancer Care by Aiding Doctors and Patients with Appropriate Treatment Assessment
2/27/2014 | Press Release
METAMARK GENETICS RECEIVES LABORATORY LICENSE IN PREPARATION TO LAUNCH ProMark™ PROSTATE-CANCER ASSAY
Metamark Genetics, Inc. today announced that its Cambridge, Mass. laboratory has been licensed for the highest level of clinical testing in the use of ProMark™, the company's prognostic assay to guide the medical management of patients with prostate cancer.
Dr. Jerome P. Richie on Prostate Cancer Awareness
In support of Prostate Cancer Awareness and the important year-round message to stay aware and well-informed of the latest news and developments in the fight against prostate cancer, Metamark’s esteemed Chief Medical Officer, Dr. Jerome P. Richie, participated in a series of radio interviews nationwide to discuss various topics around prostate cancer awareness.
Listen to an interview:
Blog Talk Radio, Ask Mom RN
KTLF-AM, The Ron and Corey Morning Show
WYCA-FM, Real Talk
See more interviews.